Glenmark Pharmaceuticals Ltd. has expanded its cardiometabolic portfolio with the introduction of Empagliflozin, a widely recognized SGLT2 inhibitor, in the Indian market. Launched under the brand name Glempa (Empagliflozin 10/25 mg), the medication is accompanied by two fixed-dose combinations (FDCs): Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).
These new offerings are specifically designed to improve glycemic control in adults with Type 2 Diabetes Mellitus (T2DM) while simultaneously reducing cardiovascular outcomes in patients with established cardiovascular risk factors.
Clinical Evidence Supporting Empagliflozin's Efficacy
Empagliflozin has established itself globally as an effective treatment for heart failure, T2DM, and T2DM with established cardiovascular disease (CVD). The landmark EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning the drug as a significant advancement for T2DM patients with high cardiovascular risks.
Multiple studies have confirmed the effectiveness of Empagliflozin and its combinations:
-
A 24-week study found that twice-daily administration of Empagliflozin (12.5 mg) with Metformin (500/1000 mg) helped T2DM patients achieve significant improvements, including:
- HbA1c reduction of 1.9% to 2.1%
- Weight loss of 3 to 3.8 kg
- Fasting blood sugar reduction of 43.2 to 50.4 mg/dL
-
Another 24-week study demonstrated that the combination of Empagliflozin (10/25 mg) with Linagliptin (5 mg) provided superior results compared to either medication alone:
- HbA1c reduction of 1.24%
- Weight loss of 2 to 2.7 kg
- Fasting blood sugar reduction of 28.21 to 29.55 mg/dL
Comprehensive Treatment Options for Diverse Patient Needs
The Glempa range offers three distinct treatment options, enhancing flexibility for healthcare providers in managing T2DM patients:
-
Glempa (Empagliflozin 10mg/25mg): A standalone SGLT2 inhibitor that improves glycemic control while reducing cardiovascular risks.
-
Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg): A dual-action therapy combining an SGLT2 inhibitor with a DPP4 inhibitor for more effective management of T2DM with cardio-renal risks.
-
Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg): Combines SGLT2 inhibition with the proven efficacy of Metformin, making it an optimal choice for patients requiring stronger glycemic control.
Addressing a Growing Health Crisis
With cardiovascular diseases and diabetes cases rising significantly in India, Glenmark's introduction of the Glempa range aims to provide affordable, high-quality treatment options that can improve health outcomes for millions of patients across the country.
"Glenmark has a strong legacy of introducing innovative and accessible treatments for Cardiometabolic care in India. The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively," said Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals Ltd.
Company Profile
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a strong presence in branded, generic, and OTC segments. The company focuses on several therapeutic areas including cardiometabolic, respiratory, dermatology, and oncology. Operating 11 manufacturing facilities across four continents, Glenmark maintains an active presence in over 80 countries.
The company's stock has shown strong performance, delivering a return of 46.55% over the past year and an impressive 208.95% over three years, classifying it as a multibagger stock. As of the latest data, Glenmark's stock is priced at Rs 1380.75, with a market capitalization exceeding Rs 39,000 crore.
